Two National Guard members shot near White House
FRANKLIN LAKES, N.J. - BD (Becton, Dickinson and Company) (NYSE:BDX), a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $55.24 billion, announced Monday the launch of its BD Surgiphor Surgical Wound Irrigation System in Europe following CE approval.
The sterile, ready-to-use irrigation solution is designed to loosen and remove debris from surgical wounds during procedures. According to the company, the system helps reduce bacterial load that could lead to infection, as demonstrated in a simulated animal model.
"Surgical Site Infections are multifactorial and continue to present serious challenges to both patient outcomes and healthcare systems," said Rian Seger, worldwide president of BD Surgery, in a press release statement.
The system is now available in select European countries and features a pre-mixed, sterile solution that eliminates preparation time before surgery. The company states the product uses an antiseptic as a preservative in the solution.
BD Surgiphor’s design allows surgical teams to apply the solution during procedures, potentially helping hospitals operate more efficiently while supporting patient outcomes.
BD, which employs more than 70,000 people globally, develops medical technology, services and solutions for healthcare providers. The company has operations in numerous countries worldwide.
This article is based on information from a company press release.
In other recent news, Becton, Dickinson and Company reported its fourth-quarter earnings for 2025, showing a slight beat in earnings per share (EPS) but narrowly missing revenue expectations. The company achieved an EPS of $3.96, slightly above the forecast of $3.92. However, revenue fell short of projections, coming in at $5.9 billion compared to the anticipated $5.91 billion. Additionally, Becton Dickinson announced the appointment of two new independent directors, Robert L. Huffines and Jacqueline Wright, to its Board of Directors, effective December 1, 2025. This move will expand the board from twelve to fourteen members. Huffines brings over 30 years of healthcare investment banking experience, while Wright adds expertise from the tech sector. These appointments reflect the company’s commitment to strengthening its governance with diverse expertise.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.